CliffBio
small molecule

FLUXID

FAMOTIDINE

Loss of exclusivity—loss of exclusivity
CompanyUCB →See this company's full patent-cliff portfolio

Drug detail

Brand nameFLUXID
Active ingredientFAMOTIDINE
Strength20MG
Dosage formTABLET, ORALLY DISINTEGRATING
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2004
Marketing statusDISCN

More from UCB

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.